Diabetes Combos: Novo, Sanofi May Need New Treatment Paradigm To Match Products
Stepwise approach of endocrinologists may have to change to maximize uptake of insulin/GLP-1 combinations.
You may also be interested in...
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.
Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.